Allorion Therapeutics
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Allorion Therapeutics - overview
Established
2020
Location
Guangzhou, Guangdong, China
Primary Industry
Biotechnology
About
Based in Guangzhou, China, and established in 2020, Allorion Therapeutics Inc. is a drug development that focuses on developing the next generation of targeted drugs for cancer and autoimmune diseases. The company team is comprised of experts in cancer biology and drug development. It has dual sites operating in Natick, Massachusetts, and Guangzhou, China.
As of 2023, the company has 53 employees. Gregory Berk, Chief Medical Officer of the company, has served as the clinical senior vice president and chief medical officer of many well-known biotechnology and biomedical companies in the United States. The company-developed fields include selecting validated targets with clear clinic development routes and discovering their modulators with distinct mechanisms of action, building data, and screening platforms, constructing and optimizing chemical libraries with allosteric and covalent modulators. Its main products include TYK2ARTS-011 and CDK2ARTS-021, etc.
The company's products are used in diseases such as cancer and tumors.
Current Investors
Qiming Venture Partners, IDG Capital, MED-FINE Capital
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biotechnology, Healthcare, Oncology/Cancer Treatment, Pharmaceuticals
Website
www.alloriontx.com
Company Stage
Series B
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.